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Methods
• In vitro PK data for rilpivirine (RPV) and cabotegravir
(CBV) was integrated into PBPK models using MATLAB,
R2013b.
• The models were validated against available clinical data
(800 mg CBV and 900 mg RPV) for the LA formulations
in adults. Drug release rate from the site of injection for
RPV and CBV was derived from the clinical data in
adults during the validation process.
• The anatomy and physiology of children aged between
3-18 years was also validated against data available in
literature [2-4].
• The weight band categories were selected according to
the World Health Organisation recommendations [5].
• ARV PK was simulated for 200 paediatric patients for
each weight band following IM administration of LA
CBV and RPV.
Results
• Weights and blood flow rates of children/adolescents at different ages
were validated against available anthropometric and anatomical data.
[2]. Parameters of existing available adult IM formulations of
cabotegravir and rilpivirine were validated against available clinical
data [3].
• The mean values of AUC were 4467 vs. 5257 µg.h/ml, Cmax 3.3 vs. 3.54
µg/ml and Ctrough 1.1 vs. 1.2 µg/ml for 800 mg CBV quarterly
intramuscular administration (Figure 2b) [5,6].
• The mean values of AUC for 900 mg IM RPV monthly administration
were 74,420 vs. 91,087 ng.h/ml, Cmax 168 vs. 168.7 ng/ml and Ctrough
79.1 vs. 78.3 ng/ml (Figure 2a) [3].
• The summary of the predicted doses for CBV and RPV for all weight
categories (according to WHO guidelines) are shown in Table 2.
• Optimal ARV doses resulting in at least 95 % of the patients
achieving Ctrough over the cut-off values for quarterly or monthly
administration of CBV or RPV were predicted.
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Conclusion
• The validated PBPK models predicted the in vivo
pharmacokinetics of CBV and RPV in children and
adolescents.
• This data could assist in the dose optimisation of
LA IM ARVs for paediatric patients.
•Modelling approach could be an innovative way
to optimise dose requirements in special
population, broadening usage in ARV therapy.
•Role of transporters, immune system, drug
diffusion through the lymphatic system during
long term therapy represent potential
limitations which have not been considered in
these PBPK models.
•PBPK model represents a predictive tool to
improve dosing strategies thus potentially
simplifying antiretroviral therapy.
Cabotegravir Rilpivirine
logP 2.2 4.32
pKa 4.14 3.26
Fu 0.007 0.003
B/P 0.441 0.67
Vss (L) - -
Clint CYP3A4 
(µL/min/pmol)
- 2.04
Clint UGT1A1 
(µL/min/pmol)
4.5 -
Clint UGT1A9 
(µL/min/pmol)
2.2 -
IM Release rate (h-1) 0.000454 0.009
Figure 2. Validation of PBPK model against
against available clinical data a) 800 mg CBV and 
900 mg RPV for the LA formulations in adults [3] 
Table 2. Optimised doses of Rilpivirine and Cabotegravir long-acting formulations for various weights 
categories of children and adolescents
a)
b)
Table 1. Physicochemical and metabolic characteristics 
of simulated drugs
# 442
Overview
• Long-acting (LA) sustained release ARVs in
children and adolescents could represent a
valuable pharmacological option, to simplify
regimens, reduce drug costs and improve
adherence for treatment and PrEP [1].
• Dose optimisation in paediatric patients is
complicated due to the differences in
anatomical and physiological process compared
to adults [2].
• Physiologically-based pharmacokinetic (PBPK)
modelling represents a mathematical approach
to predict pharmacokinetics, through the
description of molecular and physiological
processes defining drug distribution.
• The aim of this study was to simulate the
pharmacokinetics (PK) of LA intramuscular (IM)
ARVs in children and adolescents and to
identify optimal doses using PBPK modelling.
Figure 1. Variability in in vitro data and mathematical 
equations defining the physiology of an individual 
yield pharmacokinetics of a population
